News and updates from the Neotis team.
ARDD 2026 accepts abstract for poster presentation
ARDD 2026, the 13th Aging Research and Drug Discovery meeting in Boston, accepted the Neotis abstract for a poster covering the discovery platform and progress on the lead programme.
ReadAging and Senescence: From Evolution to Disease hosts an invited talk
CSO Michael Saitakis gave an invited talk at the meeting organised by the SenCode team at Inserm, which brings together the French and European senescence community.
ReadERS Congress accepts abstract for poster presentation
The European Respiratory Society Congress in Barcelona accepted the Neotis abstract, co-authored with Institut Curie, on cell-surface targets on aberrant epithelial cells in IPF patient tissue.
ReadToby Maher joins the Scientific Advisory Board
Prof. Toby Maher, interstitial lung disease specialist at USC and Imperial College London, joined the Neotis Scientific Advisory Board.
ReadServier Summer Business Connect pitched by Cathal Meehan, CEO
Cathal Meehan, Co-founder and CEO, presented Neotis at the Summer Business Connect hosted by Servier and BioLabs, putting the IPF programme in front of Servier R&D and business development teams.
ReadSFBVie Scientific Advisory Board seats both co-founders
The Société Française de Biologie du Vieillissement seated both co-founders on its Scientific Advisory Board, asking Neotis to represent translation to medicine, public health and industry.
ReadAP-HP Bichat collaboration opens access to patient tissue
Hôpital Bichat (AP-HP) brought its pulmonology, pathology and research teams into the programme, including one of the leading IPF centres in France.
ReadPfizer Golden Ticket won, with residency at BioLabs Hôtel-Dieu
The Pfizer x BioLabs Golden Ticket was awarded to Neotis at the final pitch event, carrying residency at BioLabs Hôtel-Dieu in the centre of Paris.
ReadCellAction collaboration signed with Institut Curie
CellAction, the immunotherapy acceleration platform at Institut Curie, has entered a research collaboration with Neotis to validate transmembrane targets in IPF patient biopsies.
Read€1.6M pre-seed closed
A €1.6M pre-seed round combining equity from Daphni with non-dilutive funding from Bpifrance, taking the company through target validation and antibody discovery in idiopathic pulmonary fibrosis.
Read
